Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
The 2023 Vaccine Market Report
... largely by the recent commercialization of the COVID-19 vaccine in the U.S. The U.S. vaccine market alone is projected to increase 47% from $23.8 billion in 2023 to $35.1 billion in 2030. Updated COVID-19 Vaccines ... Read More
-
Schizophrenia Drugs Market, Size, Global Forecast Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis
... Schizophrenia is a complex, chronic mental health disorder characterized by various symptoms, including delusions, hallucinations, disorganized speech or behavior, and impaired cognitive ability. The early onset of the disease, along with its chronic course, makes ... Read More
-
Chronic Hepatitis B - Market Insight, Epidemiology And Market Forecast - 2032
... across the 7MM since many people go undiagnosed. In 2022, the market size of Chronic Hepatitis B was highest in the US among the 7MM accounting for approximately USD 1,500 million, is expected to increase ... Read More
-
Gout Market Research Report Forecast till 2030
... a year old, have a high measure of uric corrosive in their blood. As per studies, its commonness and frequency have expanded over the most recent couple of many years. The rising commonness of gout ... Read More
-
Dermatomyositis - Market Insight, Epidemiology And Market Forecast - 2032
... dermatomyositis was highest in the US among the 7MM countries, accounting for approximately USD 139.3 million. It is expected to increase by 2032. Even though corticosteroids are the most prescribed class of drugs for the ... Read More
-
Sickle Cell Disease - Market Insight, Epidemiology And Market Forecast - 2032
... abnormal shape leads to complications, including chronic pain, organ damage, and increased infection susceptibility. The primary cause of SCD is a mutation in the HBB gene, which affects the production of hemoglobin. Individuals with SCD ... Read More
-
REMD-477 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the REMD-477 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
TC-210 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the TC-210 for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
PK101 Emerging Drug Insight and Market Forecast − 2032
... the PK101 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
NAMUSCLA Emerging Drug Insight and Market Forecast − 2032
... picture of the NAMUSCLA for myotonic dystrophy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
SIMPONI Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the SIMPONI for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 ... Read More
-
Hypertriglyceridemia- Pipeline Insight, 2023
... products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Hypertriglyceridemia: Understanding Hypertriglyceridemia: Overview ... Read More
-
Dercum’s Disease Market Research Report Forecast till 2030
... exercises are driving market development. Uncommon diseases, for example, adiposis dolorosa, and lipomas alongside the continuous Coronavirus pandemic, represent a significant weight worldwide. As per the NCBI study, held in February 2021, roughly 2500 individuals ... Read More
-
Itacitinib Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the itacitinib for bronchiolitis obliterans syndrome in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is ... Read More
-
HPAPI and Cytotoxic Drug Manufacturing Market (4th Edition), 2022-2035
... and cytotoxic drugs have emerged as one of the key areas of interest for researchers and drug developers worldwide. As is well known, HPAPIs are pharmacologically active compounds which are capable of eliciting a biological ... Read More
-
Exosome Therapeutics Market, 2022-2035
... including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. ... Read More
-
TEMODAR Drug Insight and Market Forecast − 2032
... the TEMODAR for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along ... Read More
-
Lurbinectedin Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the lurbinectedin for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
ONCOS-102 Emerging Drug Insight and Market Forecast − 2032
... detailed picture of the ONCOS-102 for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in ... Read More
-
SM04690 Emerging Drug Insight and Market Forecast − 2032
... the SM04690 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 –2032 is provided in ... Read More
-
FLUAD QUADRIVALENT Drug Insight and Market Forecast − 2032
... picture of the FLUAD QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this ... Read More
-
FLUBLOK QUADRIVALENT Drug Insight and Market Forecast − 2032
... picture of the FLUBLOK QUADRIVALENT for seasonal influenza in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this ... Read More
-
DELYTACT Drug Insight and Market Forecast − 2032
... the DELYTACT for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along ... Read More
-
Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast − 2032
... the seven major markets. A detailed picture of the lerapolturev + pembrolizumab for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the ... Read More
-
PRV-031 Drug Insight and Market Forecast − 2032
... of the PRV-031 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided ... Read More
Research Assistance
